Photobiomodulation as a preventive strategy for oral mucositis in pediatric oncology: a systematic review and meta-analysis

IF 5.5 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of dentistry Pub Date : 2025-08-30 DOI:10.1016/j.jdent.2025.106074

Mariana Takatu Marques , Lívia Trevelin Arêde , João Victor Soares Rodrigues , Wilton Mitsunari Takeshita , Valdir Gouveia Garcia , Rafael Scaf de Molon , Letícia Helena Theodoro

{"title":"Photobiomodulation as a preventive strategy for oral mucositis in pediatric oncology: a systematic review and meta-analysis","authors":"Mariana Takatu Marques , Lívia Trevelin Arêde , João Victor Soares Rodrigues , Wilton Mitsunari Takeshita , Valdir Gouveia Garcia , Rafael Scaf de Molon , Letícia Helena Theodoro","doi":"10.1016/j.jdent.2025.106074","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Oral mucositis (OM) is one of the most frequent and debilitating complications in children undergoing treatment for hematologic malignancies. Current management strategies focus on minimizing OM severity and alleviating symptoms. This systematic review aimed to evaluate the effectiveness of photobiomodulation (PBM) in preventing OM in pediatric patients with hematologic malignancies receiving chemotherapy.</div></div><div><h3>Data/Sources</h3><div>Guided by the PICOS framework, this review addressed the following research question: Is PBM therapy effective in reducing the incidence and severity of oral mucositis in children and adolescents with hematologic malignancies undergoing chemotherapy? A comprehensive search was conducted in PubMed, Scopus, Web of Science, Embase and The Cochrane databases through February 2025. Eligible studies were randomized clinical trials involving patients aged 0–22 years diagnosed with hematologic malignancies treated by means of chemotherapy, and undergoing preventive PBM therapy for OM.</div></div><div><h3>Study Selection</h3><div>Five randomized controlled trials were included, encompassing patients aged 4 months to 22 years. Of these, 97 received low-level laser therapy (LLLT) and 80 received light-emitting diode therapy (LEDT). PBM was consistently reported as effective in preventing the onset and reducing the severity of OM in these populations. Three studies were eligible for meta-analysis, which demonstrated a statistically significant benefit of PBM therapy (<em>p</em> = 0.04), with a 95% confidence interval ranging from 0.01 to 0.84.</div></div><div><h3>Conclusions</h3><div>PBM therapy appears to be an effective preventive strategy for oral mucositis in pediatric patients undergoing chemotherapy for hematologic malignancies. Further large-scale trials are warranted to establish standardized protocols and optimize treatment outcomes.</div></div><div><h3>Clinical Significance</h3><div>PBM therapy significantly reduces the incidence and severity of oral mucositis in pediatric patients undergoing chemotherapy for hematologic malignancies. This non-invasive intervention offers an emerging preventive strategy, improving patient comfort and treatment adherence. Standardized PBM protocols may enhance supportive care in pediatric oncology settings.</div></div>","PeriodicalId":15585,"journal":{"name":"Journal of dentistry","volume":"162 ","pages":"Article 106074"},"PeriodicalIF":5.5000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of dentistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0300571225005202","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Oral mucositis (OM) is one of the most frequent and debilitating complications in children undergoing treatment for hematologic malignancies. Current management strategies focus on minimizing OM severity and alleviating symptoms. This systematic review aimed to evaluate the effectiveness of photobiomodulation (PBM) in preventing OM in pediatric patients with hematologic malignancies receiving chemotherapy.

Data/Sources

Guided by the PICOS framework, this review addressed the following research question: Is PBM therapy effective in reducing the incidence and severity of oral mucositis in children and adolescents with hematologic malignancies undergoing chemotherapy? A comprehensive search was conducted in PubMed, Scopus, Web of Science, Embase and The Cochrane databases through February 2025. Eligible studies were randomized clinical trials involving patients aged 0–22 years diagnosed with hematologic malignancies treated by means of chemotherapy, and undergoing preventive PBM therapy for OM.

Study Selection

Five randomized controlled trials were included, encompassing patients aged 4 months to 22 years. Of these, 97 received low-level laser therapy (LLLT) and 80 received light-emitting diode therapy (LEDT). PBM was consistently reported as effective in preventing the onset and reducing the severity of OM in these populations. Three studies were eligible for meta-analysis, which demonstrated a statistically significant benefit of PBM therapy (p = 0.04), with a 95% confidence interval ranging from 0.01 to 0.84.

Conclusions

PBM therapy appears to be an effective preventive strategy for oral mucositis in pediatric patients undergoing chemotherapy for hematologic malignancies. Further large-scale trials are warranted to establish standardized protocols and optimize treatment outcomes.

Clinical Significance

PBM therapy significantly reduces the incidence and severity of oral mucositis in pediatric patients undergoing chemotherapy for hematologic malignancies. This non-invasive intervention offers an emerging preventive strategy, improving patient comfort and treatment adherence. Standardized PBM protocols may enhance supportive care in pediatric oncology settings.

查看原文本刊更多论文

光生物调节作为儿科肿瘤学口腔黏膜炎的预防策略：系统综述和荟萃分析。

目的：口腔黏膜炎（OM）是儿童接受血液恶性肿瘤治疗时最常见和最衰弱的并发症之一。目前的管理战略侧重于尽量减少OM的严重程度和减轻症状。本系统综述旨在评估光生物调节（PBM）在接受化疗的儿科血液恶性肿瘤患者中预防OM的有效性。数据/来源：在PICOS框架的指导下，本综述探讨了以下研究问题：PBM治疗是否能有效降低接受化疗的儿童和青少年血液恶性肿瘤患者口腔黏膜炎的发生率和严重程度？在PubMed， Scopus, Web of Science， Embase和Cochrane数据库中进行了全面的搜索，截止到2025年2月。符合条件的研究是随机临床试验，涉及年龄0-22岁的诊断为血液系统恶性肿瘤的患者，接受化疗，并接受预防性PBM治疗OM。研究选择：纳入5项随机对照试验，涵盖4个月至22岁的患者。其中97人接受低水平激光治疗（LLLT）， 80人接受发光二极管治疗（LEDT）。在这些人群中，PBM一直被报道为有效预防OM的发病和降低其严重程度。三项研究符合meta分析的条件，显示PBM治疗的统计学显著获益（p = 0.04），95%置信区间为0.01 ~ 0.84。结论：PBM治疗似乎是一种有效的预防口腔黏膜炎的策略在儿科患者接受化疗的血液恶性肿瘤。有必要进一步进行大规模试验，以建立标准化方案并优化治疗结果。临床意义：PBM治疗可显著降低儿科血液恶性肿瘤化疗患者口腔黏膜炎的发生率和严重程度。这种非侵入性干预提供了一种新兴的预防策略，提高了患者的舒适度和治疗依从性。标准化的PBM协议可以加强儿科肿瘤学环境中的支持性护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of dentistry 医学-牙科与口腔外科

CiteScore

7.30

自引率

11.40%

发文量

349

审稿时长

35 days

期刊介绍： The Journal of Dentistry has an open access mirror journal The Journal of Dentistry: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. The Journal of Dentistry is the leading international dental journal within the field of Restorative Dentistry. Placing an emphasis on publishing novel and high-quality research papers, the Journal aims to influence the practice of dentistry at clinician, research, industry and policy-maker level on an international basis. Topics covered include the management of dental disease, periodontology, endodontology, operative dentistry, fixed and removable prosthodontics, dental biomaterials science, long-term clinical trials including epidemiology and oral health, technology transfer of new scientific instrumentation or procedures, as well as clinically relevant oral biology and translational research. The Journal of Dentistry will publish original scientific research papers including short communications. It is also interested in publishing review articles and leaders in themed areas which will be linked to new scientific research. Conference proceedings are also welcome and expressions of interest should be communicated to the Editor.